<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33993224</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1537-6591</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>74</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
          <ISOAbbreviation>Clin Infect Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community-Vermont, 2018.</ArticleTitle>
        <Pagination>
          <StartPage>455</StartPage>
          <EndPage>460</EndPage>
          <MedlinePgn>455-460</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciab450</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">In 2018, the Centers for Disease Control and Prevention and the Vermont Department of Health investigated an outbreak of multidrug-resistant Shigella sonnei infections in a retirement community that offered a continuum of care from independent living through skilled nursing care. The investigation identified 24 culture-confirmed cases. Isolates were resistant to trimethoprim-sulfamethoxazole, ampicillin, and ceftriaxone, and had decreased susceptibility to azithromycin and ciprofloxacin.</AbstractText>
          <AbstractText Label="METHODS">To evaluate clinical and microbiologic response, we reviewed inpatient and outpatient medical records for treatment outcomes among the 24 patients with culture-confirmed S. sonnei infection. We defined clinical failure as diarrhea (≥3 loose stools per day) for ≥1 day after treatment finished, and microbiologic failure as a stool culture that yielded S. sonnei after treatment finished. We used broth microdilution to perform antimicrobial susceptibility testing, and whole genome sequencing to identify resistance mechanisms.</AbstractText>
          <AbstractText Label="RESULTS">Isolates contained macrolide resistance genes mph(A) and erm(B) and had azithromycin minimum inhibitory concentrations above the Clinical and Laboratory Standards Institute epidemiological cutoff value of ≤16 µg/mL. Among 24 patients with culture-confirmed Shigella infection, 4 were treated with azithromycin; all had clinical treatment failure and 2 also had microbiologic treatment failure. Isolates were susceptible to ciprofloxacin but contained a gyrA mutation; 2 patients failed treatment with ciprofloxacin.</AbstractText>
          <AbstractText Label="CONCLUSIONS">These azithromycin treatment failures demonstrate the importance of clinical breakpoints to aid clinicians in identifying alternative treatment options for resistant strains. Additionally, these treatment failures highlight a need for comprehensive susceptibility testing and systematic outcome studies, particularly given the emergence of multidrug-resistant Shigella among an expanding range of patient populations.</AbstractText>
          <CopyrightInformation>Published by Oxford University Press for the Infectious Diseases Society of America 2021.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gharpure</LastName>
            <ForeName>Radhika</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-0702-5628</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Friedman</LastName>
            <ForeName>Cindy R</ForeName>
            <Initials>CR</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fialkowski</LastName>
            <ForeName>Veronica</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Vermont Department of Health, Burlington, Vermont, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Collins</LastName>
            <ForeName>Jennifer P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strysko</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marsh</LastName>
            <ForeName>Zachary A</ForeName>
            <Initials>ZA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jessica C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meservey</LastName>
            <ForeName>Elizabeth H</ForeName>
            <Initials>EH</Initials>
            <AffiliationInfo>
              <Affiliation>Weems Design Studio, Inc, Suwanee, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adediran</LastName>
            <ForeName>Azizat A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schroeder</LastName>
            <ForeName>Morgan N</ForeName>
            <Initials>MN</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wadhwa</LastName>
            <ForeName>Ashutosh</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fullerton</LastName>
            <ForeName>Kathleen E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Francois Watkins</LastName>
            <ForeName>Louise</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CC999999</GrantID>
            <Acronym>ImCDC</Acronym>
            <Agency>Intramural CDC HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Infect Dis</MedlineTA>
        <NlmUniqueID>9203213</NlmUniqueID>
        <ISSNLinking>1058-4838</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5E8K9I0O4U</RegistryNumber>
          <NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>83905-01-5</RegistryNumber>
          <NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002939" MajorTopicYN="N">Ciprofloxacin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004405" MajorTopicYN="Y">Dysentery, Bacillary</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012179" MajorTopicYN="N">Retirement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012760" MajorTopicYN="Y">Shigella</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012764" MajorTopicYN="N">Shigella sonnei</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014707" MajorTopicYN="N" Type="Geographic">Vermont</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">
          Shigella sonnei
        </Keyword>
        <Keyword MajorTopicYN="Y">antibiotic treatment failure</Keyword>
        <Keyword MajorTopicYN="Y">azithromycin</Keyword>
        <Keyword MajorTopicYN="Y">ciprofloxacin</Keyword>
        <Keyword MajorTopicYN="Y">multidrug resistance</Keyword>
      </KeywordList>
      <CoiStatement><b><i>Potential conflicts of interest</i>.</b> The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>20</Hour>
          <Minute>58</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33993224</ArticleId>
        <ArticleId IdType="mid">NIHMS1790552</ArticleId>
        <ArticleId IdType="pmc">PMC8963682</ArticleId>
        <ArticleId IdType="doi">10.1093/cid/ciab450</ArticleId>
        <ArticleId IdType="pii">6276522</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: CDC, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Shane AL, Mody RK, Crump JA, et al.
2017
Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis
2017; 65:e4580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5850553</ArticleId>
            <ArticleId IdType="pubmed">29053792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Academy of Pediatrics. Shigella infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases Vol. 2012. Elk Grove Village, IL: American Academy of Pediatrics, 2012:6457.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System (NARMS) Now: human data. Available at: https://www.cdc.gov/narmsnow.
Accessed
20 April 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Baker KS, Dallman TJ, Ashton PM, et al.
Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis
2015; 15:91321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25936611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 31st ed.
CLSI supplement M100. Wayne, PA: CLSI, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. HAN00411: update—CDC recommendations for managing and reporting Shigella infections with possible reduced susceptibility to ciprofloxacin. Atlanta, GA: CDC, 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Strysko J, Fialkowski V, Marsh Z, et al.
Notes from the field: outbreak of multidrug-resistant Shigella sonnei infections in a retirement community—Vermont, OctoberNovember 2018. MMWR Morb Mortal Wkly Rep
2019; 68:405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6541310</ArticleId>
            <ArticleId IdType="pubmed">31048673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. Antibiotics tested by NARMS. Available at: https://www.cdc.gov/narms/antibiotics-tested.html.
Accessed
13 December 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 30th ed.
CLSI supplement M100
Wayne, PA: CLSI, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Zankari E, Hasman H, Cosentino S, et al.
Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother
2012; 67:26404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3468078</ArticleId>
            <ArticleId IdType="pubmed">22782487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. J Antimicrob Chemother
2017; 72:27648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5890747</ArticleId>
            <ArticleId IdType="pubmed">29091202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunt M, Mather AE, Sánchez-Busó L, et al.
ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. Microb Genom
2017; 3:e000131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5695208</ArticleId>
            <ArticleId IdType="pubmed">29177089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med
1997; 126:697703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9139555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J
2003; 22:3747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12712971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boumghar-Bourtchai L, Mariani-Kurkdjian P, Bingen E, et al.
Macrolide-resistant Shigella sonnei. Emerg Infect Dis
2008; 14:12979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2600399</ArticleId>
            <ArticleId IdType="pubmed">18680661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassing RJ, Melles DC, Goessens WH, Rijnders BJ. Case of Shigella flexneri infection with treatment failure due to azithromycin resistance in an HIV-positive patient. Infection
2014; 42:78990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24488332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houpt ER, Ferdous T, Ara R, et al.
Clinical outcomes of drug-resistant shigellosis treated with azithromycin in Bangladesh. Clin Infect Dis
2021; 72:17938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32239137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med
1992; 117:72734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1416574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis
1990; 162:7116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2201742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis
2005; 41(Suppl 2):S14457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15942881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins JP, Friedman CR, Birhane MG, et al.
Evidence of failure of oral third-generation cephalosporin treatment for Shigella sonnei infection. Open Forum Infect Dis
2020; 7:ofaa113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7175969</ArticleId>
            <ArticleId IdType="pubmed">32341933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang Z, Zhang J, Ran L, et al.
The changing epidemiology of bacillary dysentery and characteristics of antimicrobial resistance of Shigella isolated in China from 20042014. BMC Infect Dis
2016; 16:685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5116132</ArticleId>
            <ArticleId IdType="pubmed">27863468</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
